Immatics NV
IMTX10.220USD
-0.150-1.45%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
1.24BMarket Cap
LossP/E TTM
More Details of Immatics NV Company
Immatics NV is a clinical-stage biopharmaceutical company that is based in the Netherlands. The Company is focused on the discovery and development of T-Cell eceptors with the goal of enabling a robust and specific T-Cell response against these targets. The Company develops targeted immunotherapies with an emphasis on treating solid tumors through two distinct therapeutic modalities: Adoptive Cell Therapies (ACT) and antibody-like TCR Bispecifics (TCER). Its wholly owned pipeline comprises of eight therapeutic programs, of which four are in clinical trials, including IMA201 (MAGEA4/8), IMA202 (MAGEA1) and ACTolog IMA 101 (Multi-target pilot trial) for solid cancers and IMA203 (PRAME) for hematological and solid cancers, as well as four are in preclinical development, including IMA204 (COL6A3) and IMA401 (Cancer testis antigen) for solid cancers, and ACTallo IMA301 (Cancer testis antigen) and IMA402 (Cancer testis antigen) for hematological and solid cancers.
Immatics NV Info
Ticker SymbolIMTX
Company nameImmatics NV
IPO dateJul 02, 2020
CEOSingh (Harpreet)
Number of employees297
Security typeOrdinary Share
Fiscal year-endJul 02
AddressPaul Ehrlich-Strasse 15
CityTUEBINGEN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryGermany
Postal code72076
Phone4970715397700
Websitehttps://immatics.com/
Ticker SymbolIMTX
IPO dateJul 02, 2020
CEOSingh (Harpreet)
Company Executives of Immatics NV
Name
Name/Position
Position
Shareholding
Change
Mr. Peter Chambre
Mr. Peter Chambre
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
405.15K
+8.54%
Dr. Steffen Walter, Ph.D.
Dr. Steffen Walter, Ph.D.
Chief Operating Officer
Chief Operating Officer
380.70K
+36.02%
Dr. Mathias Hothum, Ph.D.
Dr. Mathias Hothum, Ph.D.
Non-Executive Director
Non-Executive Director
354.52K
+7.59%
Mr. Jordan Silverstein
Mr. Jordan Silverstein
Head of Strategy
Head of Strategy
282.48K
+44.00%
Mr. Arnd Christ
Mr. Arnd Christ
Chief Financial Officer
Chief Financial Officer
276.84K
+62.94%
Mr. Edward Sturchio
Mr. Edward Sturchio
General Counsel
General Counsel
200.00K
+87.14%
Mr. Paul Rutherford Carter
Mr. Paul Rutherford Carter
Non-Executive Independent Director
Non-Executive Independent Director
87.19K
+57.63%
Mr. Michael G. (Mike) Atieh
Mr. Michael G. (Mike) Atieh
Non-Executive Independent Director
Non-Executive Independent Director
87.19K
+57.63%
Dr. Alise S. Reicin, M.D.
Dr. Alise S. Reicin, M.D.
Temporary Non-Executive Director
Temporary Non-Executive Director
10.00K
--
Mr. Adam Stone
Mr. Adam Stone
Non-Executive Independent Director
Non-Executive Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Peter Chambre
Mr. Peter Chambre
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
405.15K
+8.54%
Dr. Steffen Walter, Ph.D.
Dr. Steffen Walter, Ph.D.
Chief Operating Officer
Chief Operating Officer
380.70K
+36.02%
Dr. Mathias Hothum, Ph.D.
Dr. Mathias Hothum, Ph.D.
Non-Executive Director
Non-Executive Director
354.52K
+7.59%
Mr. Jordan Silverstein
Mr. Jordan Silverstein
Head of Strategy
Head of Strategy
282.48K
+44.00%
Mr. Arnd Christ
Mr. Arnd Christ
Chief Financial Officer
Chief Financial Officer
276.84K
+62.94%
Mr. Edward Sturchio
Mr. Edward Sturchio
General Counsel
General Counsel
200.00K
+87.14%
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
T. Rowe Price Investment Management, Inc.
15.94%
DH Capital GmbH & Co. KG
14.15%
Baker Bros. Advisors LP
9.95%
Suvretta Capital Management, LLC
9.90%
Perceptive Advisors LLC
7.72%
Other
42.34%
Shareholders
Shareholders
Proportion
T. Rowe Price Investment Management, Inc.
15.94%
DH Capital GmbH & Co. KG
14.15%
Baker Bros. Advisors LP
9.95%
Suvretta Capital Management, LLC
9.90%
Perceptive Advisors LLC
7.72%
Other
42.34%
Shareholder Types
Shareholders
Proportion
Hedge Fund
24.26%
Investment Advisor
18.11%
Investment Advisor/Hedge Fund
17.03%
Corporation
14.15%
Private Equity
8.13%
Research Firm
7.22%
Individual Investor
4.66%
Venture Capital
1.84%
Endowment Fund
0.57%
Other
4.02%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
196
96.83M
79.67%
-17.44M
2025Q2
213
122.33M
100.64%
-17.23M
2025Q1
214
124.44M
102.37%
-14.20M
2024Q4
208
124.50M
104.31%
+7.71M
2024Q3
202
107.38M
100.53%
-7.52M
2024Q2
201
107.32M
100.55%
-1.74M
2024Q1
188
101.29M
94.78%
+19.35M
2023Q4
166
76.94M
93.30%
+2.21M
2023Q3
155
70.38M
86.16%
+3.44M
2023Q2
153
67.89M
85.91%
+7.49M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
T. Rowe Price Investment Management, Inc.
18.33M
15.08%
+3.65M
+24.88%
Jun 30, 2025
DH Capital GmbH & Co. KG
17.20M
14.15%
--
--
Jan 31, 2025
Baker Bros. Advisors LP
10.17M
8.37%
+2.89M
+39.76%
Jun 30, 2025
Suvretta Capital Management, LLC
12.03M
9.9%
+2.90M
+31.69%
Jun 30, 2025
Perceptive Advisors LLC
9.38M
7.72%
--
--
Jun 30, 2025
RTW Investments L.P.
6.97M
5.73%
+60.64K
+0.88%
Jun 30, 2025
Vestal Point Capital, LP
6.25M
5.14%
-942.70K
-13.11%
Jun 30, 2025
TD Securities, Inc.
2.91M
2.4%
-60.64K
-2.04%
Jun 30, 2025
Sofinnova Investments, Inc
2.24M
1.84%
+686.22K
+44.15%
Jun 30, 2025
Morgan Stanley & Co. LLC
2.07M
1.7%
-164.89K
-7.39%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Virtus LifeSci Biotech Clinical Trials ETF
1.12%
ALPS Medical Breakthroughs ETF
0.51%
SPDR S&P International Small Cap ETF
0.06%
SPDR Portfolio Developed World ex-US ETF
0.01%
Fidelity Nasdaq Composite Index ETF
0%
Goldman Sachs Innovate Equity ETF
0%
iShares Health Innovation Active ETF
0%
SPDR SSGA US Small Cap Low Volatility Index ETF
0%
State Street SPDR S&P Kensho New Econ Comp ETF
0%
First Trust IPOX Europe Equity Opportunities ETF
0%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion1.12%
ALPS Medical Breakthroughs ETF
Proportion0.51%
SPDR S&P International Small Cap ETF
Proportion0.06%
SPDR Portfolio Developed World ex-US ETF
Proportion0.01%
Fidelity Nasdaq Composite Index ETF
Proportion0%
Goldman Sachs Innovate Equity ETF
Proportion0%
iShares Health Innovation Active ETF
Proportion0%
SPDR SSGA US Small Cap Low Volatility Index ETF
Proportion0%
State Street SPDR S&P Kensho New Econ Comp ETF
Proportion0%
First Trust IPOX Europe Equity Opportunities ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Immatics NV?
The top five shareholders of Immatics NV are:
T. Rowe Price Investment Management, Inc. holds 18.33M shares, accounting for 15.08% of the total shares.
DH Capital GmbH & Co. KG holds 17.20M shares, accounting for 14.15% of the total shares.
Baker Bros. Advisors LP holds 10.17M shares, accounting for 8.37% of the total shares.
Suvretta Capital Management, LLC holds 12.03M shares, accounting for 9.90% of the total shares.
Perceptive Advisors LLC holds 9.38M shares, accounting for 7.72% of the total shares.
T. Rowe Price Investment Management, Inc. holds 18.33M shares, accounting for 15.08% of the total shares.
DH Capital GmbH & Co. KG holds 17.20M shares, accounting for 14.15% of the total shares.
Baker Bros. Advisors LP holds 10.17M shares, accounting for 8.37% of the total shares.
Suvretta Capital Management, LLC holds 12.03M shares, accounting for 9.90% of the total shares.
Perceptive Advisors LLC holds 9.38M shares, accounting for 7.72% of the total shares.
What are the top three shareholder types of Immatics NV?
The top three shareholder types of Immatics NV are:
T. Rowe Price Investment Management, Inc.
DH Capital GmbH & Co. KG
Baker Bros. Advisors LP
T. Rowe Price Investment Management, Inc.
DH Capital GmbH & Co. KG
Baker Bros. Advisors LP
How many institutions hold shares of Immatics NV (IMTX)?
As of 2025Q3, 196 institutions hold shares of Immatics NV, with a combined market value of approximately 96.83M, accounting for 79.67% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -20.97%.
What is the biggest source of revenue for Immatics NV?
In --, the -- business generated the highest revenue for Immatics NV, amounting to -- and accounting for --% of total revenue.
